article thumbnail

Epigenetic Editing with CRISPR + ADHD in Preschoolers – Xtalks Life Science Podcast Ep. 10

XTalks

In this episode, Ayesha discusses a new tool that uses CRISPR to modulate gene expression without editing DNA sequences. Dubbed “CRISPRoff,” the technology targets the epigenome to silence genes involved in diseases, with applications in cancer, AML and other conditions with a heritable component.

article thumbnail

Scandinavia: insight into opportunities for drug discovery

Drug Discovery World

Though not without its challenges, the life sciences industry in Scandinavia is well represented and acts as a serious contender for R&D output. More so, the Karolinska Institute is ranked at number seven in the world for the subjects of life sciences and medicine. We have 3,000 companies in the life sciences sector.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Combining the Powers of Single Cell Sequencing and AI in Understanding Disease Biology and Drug Development

XTalks

Visium Spatial Gene Expression Solution. To address challenges associated with loss of spatial context, 10x Genomics has developed the Visium Spatial Gene Expression solution, which enables answering biological questions in the context of tissue using an unbiased gene expression approach.

article thumbnail

World Glaucoma Week 2024: New Advances in Glaucoma Care

XTalks

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. Secondly, other funded research is exploring differential gene expression regulated by DNA methylation.

article thumbnail

Synthetic biology: Innovating in drug discovery

Drug Discovery World

Evonetix will use the funding to brings its semiconductor chips to commercial scale and extend gene assembly capabilities for its binary assembly technology to deliver accurate, gene-length DNA in a benchtop instrument.

Drugs 52
article thumbnail

Artificial intelligence could be new blueprint for precision drug discovery

The Pharma Data

.” In the new study, Ghosh and colleagues replaced the first and last steps in preclinical drug discovery with two novel approaches developed within the UC San Diego Institute for Network Medicine (iNetMed), which unites several research disciplines to develop new solutions to advance life sciences and technology and enhance human health.

Drugs 52
article thumbnail

Eli Lilly’s Olumiant Wins FDA Approval as First Systemic Treatment for Alopecia Areata

XTalks

It blocks the activity of JAK1 and JAK2 to interfere with the JAK-STAT signaling pathway to dampen the production of inflammatory cytokines through the modulation of gene expression. Olumiant is a Janus kinase (JAK) inhibitor that was first discovered by Incyte and then licensed to Eli Lilly.